On July 31, Illumina rose 5.27% in regular trading, trading at $205.095 per share with turnover of $4.03 billion. The rally was driven by the company's second fiscal quarter earnings report released after market close on July 30.

Illumina has now delivered consecutive quarters of above-consensus results. In Q1, adjusted EPS of $1.15 beat the $1.05 estimate by 9.52%, while revenue of $1.09 billion grew 4.8% year-over-year. The company's full-year revenue guidance of $4.52 billion to $4.62 billion exceeded the FactSet consensus of $4.54 billion. In Q4, adjusted EPS of $1.35 topped the $1.23 estimate by 10.2%, representing a 42% year-over-year increase. The board also authorized an additional $1.5 billion stock buyback program. Analyst sentiment has turned increasingly bullish, with JPMorgan upgrading the stock to Overweight in June with a $185 price target, and Daiwa Securities upgrading to Outperform in May. RBC noted that Illumina's mid-teens clinical growth appears sustainable over the next one to two years, driven by oncology testing and screening applications.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)